AR032432A1 - ONCOLITICAL COMBINATIONS FOR CANCER TREATMENT - Google Patents

ONCOLITICAL COMBINATIONS FOR CANCER TREATMENT

Info

Publication number
AR032432A1
AR032432A1 ARP000105955A ARP000105955A AR032432A1 AR 032432 A1 AR032432 A1 AR 032432A1 AR P000105955 A ARP000105955 A AR P000105955A AR P000105955 A ARP000105955 A AR P000105955A AR 032432 A1 AR032432 A1 AR 032432A1
Authority
AR
Argentina
Prior art keywords
oncolitical
combinations
cancer treatment
ltb4
effectiveness
Prior art date
Application number
ARP000105955A
Other languages
Spanish (es)
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of AR032432A1 publication Critical patent/AR032432A1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)

Abstract

Los antagonistas de leucotrieno (LTB4) mejoran la efectividad de agentes anti-cáncer de 2' û2' difluoronucleosido.Leukotriene antagonists (LTB4) improve the effectiveness of 2 'û2' difluoronucleoside anti-cancer agents.

ARP000105955A 1999-11-11 2000-11-10 ONCOLITICAL COMBINATIONS FOR CANCER TREATMENT AR032432A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US16478699P 1999-11-11 1999-11-11

Publications (1)

Publication Number Publication Date
AR032432A1 true AR032432A1 (en) 2003-11-12

Family

ID=22596085

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP000105955A AR032432A1 (en) 1999-11-11 2000-11-10 ONCOLITICAL COMBINATIONS FOR CANCER TREATMENT

Country Status (22)

Country Link
EP (1) EP1231938A2 (en)
JP (1) JP2003513916A (en)
KR (1) KR20020069512A (en)
CN (1) CN1390139A (en)
AR (1) AR032432A1 (en)
AU (1) AU778829B2 (en)
BR (1) BR0015490A (en)
CA (1) CA2391416A1 (en)
CZ (1) CZ20021551A3 (en)
EA (1) EA200200545A1 (en)
HK (1) HK1050132A1 (en)
HU (1) HUP0204449A3 (en)
IL (1) IL148579A0 (en)
MX (1) MXPA02004733A (en)
NO (1) NO20022245L (en)
NZ (1) NZ517667A (en)
PE (1) PE20010701A1 (en)
PL (1) PL355172A1 (en)
SK (1) SK6492002A3 (en)
TR (1) TR200201245T2 (en)
WO (1) WO2001034137A2 (en)
ZA (1) ZA200202822B (en)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001034198A2 (en) * 1999-11-11 2001-05-17 Eli Lilly And Company Oncolytic combinations for the treatment of cancer
WO2001034197A2 (en) * 1999-11-11 2001-05-17 Eli Lilly And Company Oncolytic combinations for the treatment of cancer
US6797723B1 (en) 1999-11-11 2004-09-28 Eli Lilly And Company Heterocycle substituted diphenyl leukotriene antagonists
JP2001247459A (en) 2000-03-03 2001-09-11 Oakland Uniservices Ltd Combination therapy for cancer
CA2408622A1 (en) * 2000-05-09 2001-11-15 Creighton University Methods for inhibiting proliferation and inducing apoptosis in cancer cells
JP2004505047A (en) 2000-07-28 2004-02-19 キャンサー・リサーチ・テクノロジー・リミテッド Cancer treatment by combined therapy
GB0121285D0 (en) 2001-09-03 2001-10-24 Cancer Res Ventures Ltd Anti-cancer combinations
GB2386836B (en) 2002-03-22 2006-07-26 Cancer Res Ventures Ltd Anti-cancer combinations
GB2394658A (en) 2002-11-01 2004-05-05 Cancer Rec Tech Ltd Oral anti-cancer composition
WO2005105736A1 (en) 2004-05-05 2005-11-10 Novo Nordisk A/S Novel compounds, their preparation and use
ES2352085T3 (en) 2004-05-05 2011-02-15 High Point Pharmaceuticals, Llc NEW COMPOUNDS, THEIR PREPARATION AND USE.
CN1302782C (en) * 2005-01-17 2007-03-07 北京京卫燕康药物研究所有限公司 Jixitabing hydrochloride solution type injection agent
ATE529404T1 (en) 2005-06-30 2011-11-15 High Point Pharmaceuticals Llc PHENOXYACETIC ACIDS AS PPAR-DELTA ACTIVATORS
EP1979311B1 (en) 2005-12-22 2012-06-13 High Point Pharmaceuticals, LLC Phenoxy acetic acids as ppar delta activators
CA2645719A1 (en) 2006-03-09 2007-09-13 High Point Pharmaceuticals, Llc Compounds that modulate ppar activity, their preparation and use
AU2007307597A1 (en) 2006-10-12 2008-04-17 Institute Of Medicinal Molecular Design. Inc. Carboxylic acid derivatives
US8633245B2 (en) 2008-04-11 2014-01-21 Institute Of Medicinal Molecular Design, Inc. PAI-1 inhibitor
WO2014060381A1 (en) 2012-10-18 2014-04-24 Bayer Cropscience Ag Heterocyclic compounds as pesticides
EP2914587A1 (en) 2012-10-31 2015-09-09 Bayer CropScience AG Novel heterocyclic compounds as pest control agents
CN103319466B (en) * 2013-07-04 2016-03-16 郑州大学 Containing the 1,2,3-triazoles-dithiocarbamates compound of tonka bean camphor parent nucleus, preparation method and application thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6034256A (en) * 1997-04-21 2000-03-07 G.D. Searle & Co. Substituted benzopyran derivatives for the treatment of inflammation

Also Published As

Publication number Publication date
CN1390139A (en) 2003-01-08
PL355172A1 (en) 2004-04-05
BR0015490A (en) 2002-07-09
CZ20021551A3 (en) 2003-02-12
NO20022245L (en) 2002-07-09
NO20022245D0 (en) 2002-05-10
SK6492002A3 (en) 2003-09-11
ZA200202822B (en) 2003-09-23
HUP0204449A2 (en) 2003-04-28
PE20010701A1 (en) 2001-07-07
TR200201245T2 (en) 2004-08-23
AU1599001A (en) 2001-06-06
KR20020069512A (en) 2002-09-04
WO2001034137A2 (en) 2001-05-17
EP1231938A2 (en) 2002-08-21
WO2001034137A3 (en) 2002-02-14
HUP0204449A3 (en) 2006-02-28
IL148579A0 (en) 2002-09-12
CA2391416A1 (en) 2001-05-17
MXPA02004733A (en) 2002-08-30
JP2003513916A (en) 2003-04-15
AU778829B2 (en) 2004-12-23
HK1050132A1 (en) 2003-06-13
NZ517667A (en) 2004-05-28
EA200200545A1 (en) 2002-12-26

Similar Documents

Publication Publication Date Title
AR032432A1 (en) ONCOLITICAL COMBINATIONS FOR CANCER TREATMENT
DE69925133D1 (en) PYRROLOBENZODIAZEPINE
DE60020812D1 (en) HETEROARYL-SUBSTITUTED CHINOLIN-2-ON DERIVATIVES USE AS ANTICROBIAL AGENTS
DE60112974D1 (en) Carbolinderivate
PT1200412E (en) IMIDAZOLE ANTI-PROLIFERATIVE AGENTS
TR200200579T2 (en) Amino-thyrazolpyridine derivatives.
EA200200616A1 (en) CHEMICAL DERIVATIVES AND THEIR APPLICATION AS ANTITELOMERASE AGENT
DE60216233D1 (en) Carbolinderivate
ITTO20000211A0 (en) DELIVERY COMBINATOR DEVICE FOR THE SUPPLY OF HYDRAULIC EQUIPMENT.
SE9903997D0 (en) New compounds
SE9901077D0 (en) Novel use
DE60115466D1 (en) ACTIVE PROCESSORS OF IMIDAZOPYRIDINE DERIVATIVES
UY27203A1 (en) USEFUL BENCIMIDAZOLS IN THE TREATMENT OF SEXUAL DYSFUNCTION
DE60112960D1 (en) CONDENSED PYRIDOINDOL DERIVATIVES
IT1319267B1 (en) APPARATUS TO PREVENT THE LEAVING OF SEWING LINES.
AR022321A1 (en) USEFUL ANTI-CONVULSIVE DERIVATIVES FOR THE TREATMENT OF TRANSFORMED MIGRANE
ITRM990426A0 (en) USE OF SUBSTANCE P INHIBITORS FOR THE TREATMENT OF ADENOCARCINOMAS.
PE20010744A1 (en) USE OF (2S, 3S, 5R) -2- (3,5-DIFLUOROPHENYL) -3,5-DIMETHYL-2-MORPHOLINOL FOR THE TREATMENT OF OBESITY
MXPA03003971A (en) Indole derivatives as pde5-inhibitors.
DE60121048D1 (en) PYRAZINOi1'2 ': 1,6öPYRIDOi3,4-BöINDOLDERIVATE
WO2001034134A3 (en) Oncolytic combinations for the treatment of cancer
BR0017046A (en) Use of azoles to prevent skin cancer
NO20020914L (en) Alkoxy-substituted benzimidazole compounds, preparations containing them and their applications
ATE252896T1 (en) ENDOCRINE THERAPY FOR BREAST CANCER: COMBINED TREATMENT WITH TAMOXIFEN AND ALKYL-PCDFS
BR0007395B1 (en) s-nitrosothiol compounds as agents for the treatment of circulatory dysfunction.

Legal Events

Date Code Title Description
FB Suspension of granting procedure